SGLT-2 inhibitors (SGLT-2i) also called gliflozins differ in their relative inhibition of SGLT 1 and 2 receptors [4]. SGLT-2 inhibitors which were initially created as medications for lowering blood sugar levels showed significant outcomes such as reduced HF hospitalization and adverse kidney events in cardiovascular outcome trials [3]. Here, SLC5A2 is linked to hydrops fetalis.